The UK Competition and Markets Authority (CMA) has initiated a review of a £129m grant proposed for BioNTech by the Department for Science, Innovation and Technology (DSIT).
- The review aims to assess the compliance of the grant with subsidy control requirements, due to be finalised within 30 working days.
- BioNTech’s planned £1 billion investment into the UK is set to bolster the biotech sector, focusing on R&D and AI advancements.
- The investment is predicted to create 460 new jobs and enhance the UK’s life sciences capabilities.
- BioNTech’s new facilities will focus on significant health advancements, including drug discovery and cancer treatment.
The Competition and Markets Authority (CMA) is undertaking a critical evaluation of the Department for Science, Innovation and Technology’s (DSIT) decision to allocate a £129 million subsidy to BioNTech. This review seeks to ascertain whether the financial aid adheres to current subsidy control requirements, ensuring fair market practices.
BioNTech, a leading German biotechnology company, has committed to investing approximately £1 billion in the United Kingdom. This substantial investment is intended to catalyse growth in the UK’s biotech industry, particularly in the areas of research and development (R&D) and artificial intelligence (AI). The proposed expansion is expected to create roughly 460 jobs, reinforcing the UK’s position as a hub for scientific innovation.
The project, which includes the establishment of centres of excellence in Cambridge and London, will significantly contribute to advancements in areas such as structural biology, regenerative medicine, oncology, and AI-driven drug discovery. In particular, the Cambridge centre will focus on developing new treatments for cancer and other severe illnesses. Meanwhile, the London hub will house a centre of expertise for AI, led by BioNTech’s subsidiary, InstaDeep.
This financial incentive, governed by a comprehensive grant funding agreement, details the specific activities and permissible expenditures associated with the subsidy. The DSIT has justified this subsidy as a strategic move to overcome existing market barriers deterring R&D investment. It aligns with key objectives outlined in the government’s Life Sciences Plan, namely to enhance the UK’s R&D sector, improve health resilience, and stimulate economic growth.
The CMA’s review will be pivotal in assessing the subsidy’s alignment with regulatory standards, a crucial step in advancing the UK life sciences sector.
